Logo image of SGMO

SANGAMO THERAPEUTICS INC (SGMO) Stock Fundamental Analysis

NASDAQ:SGMO - Nasdaq - US8006771062 - Common Stock - Currency: USD

0.492  -0.01 (-1.6%)

After market: 0.495 +0 (+0.61%)

Fundamental Rating

2

Taking everything into account, SGMO scores 2 out of 10 in our fundamental rating. SGMO was compared to 560 industry peers in the Biotechnology industry. While SGMO seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, SGMO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SGMO has reported negative net income.
In the past year SGMO has reported a negative cash flow from operations.
SGMO had negative earnings in each of the past 5 years.
In the past 5 years SGMO reported 4 times negative operating cash flow.
SGMO Yearly Net Income VS EBIT VS OCF VS FCFSGMO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

The Return On Assets of SGMO (-149.17%) is worse than 84.74% of its industry peers.
With a Return On Equity value of -2620.02%, SGMO is not doing good in the industry: 83.30% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -149.17%
ROE -2620.02%
ROIC N/A
ROA(3y)-95.5%
ROA(5y)-64.82%
ROE(3y)-268.79%
ROE(5y)-175.64%
ROIC(3y)N/A
ROIC(5y)N/A
SGMO Yearly ROA, ROE, ROICSGMO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SGMO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGMO Yearly Profit, Operating, Gross MarginsSGMO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

SGMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
SGMO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SGMO has more shares outstanding
SGMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SGMO Yearly Shares OutstandingSGMO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
SGMO Yearly Total Debt VS Total AssetsSGMO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

SGMO has an Altman-Z score of -28.39. This is a bad value and indicates that SGMO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SGMO (-28.39) is worse than 89.23% of its industry peers.
SGMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -28.39
ROIC/WACCN/A
WACC9.79%
SGMO Yearly LT Debt VS Equity VS FCFSGMO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 0.76 indicates that SGMO may have some problems paying its short term obligations.
SGMO's Current ratio of 0.76 is on the low side compared to the rest of the industry. SGMO is outperformed by 89.77% of its industry peers.
SGMO has a Quick Ratio of 0.76. This is a bad value and indicates that SGMO is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.76, SGMO is not doing good in the industry: 88.87% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.76
SGMO Yearly Current Assets VS Current LiabilitesSGMO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

SGMO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.03%, which is quite impressive.
The Revenue has grown by 243.09% in the past year. This is a very strong growth!
The Revenue for SGMO have been decreasing by -10.81% on average. This is quite bad
EPS 1Y (TTM)79.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.15%
Revenue 1Y (TTM)243.09%
Revenue growth 3Y-19.48%
Revenue growth 5Y-10.81%
Sales Q2Q%1238.25%

3.2 Future

SGMO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.20% yearly.
Based on estimates for the next years, SGMO will show a very strong growth in Revenue. The Revenue will grow by 35.71% on average per year.
EPS Next Y28.04%
EPS Next 2Y14.12%
EPS Next 3Y15.86%
EPS Next 5Y12.2%
Revenue Next Year-11.11%
Revenue Next 2Y-6.16%
Revenue Next 3Y19.6%
Revenue Next 5Y35.71%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SGMO Yearly Revenue VS EstimatesSGMO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
SGMO Yearly EPS VS EstimatesSGMO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SGMO. In the last year negative earnings were reported.
Also next year SGMO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGMO Price Earnings VS Forward Price EarningsSGMO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGMO Per share dataSGMO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

A more expensive valuation may be justified as SGMO's earnings are expected to grow with 15.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.12%
EPS Next 3Y15.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGMO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SANGAMO THERAPEUTICS INC

NASDAQ:SGMO (7/11/2025, 8:00:02 PM)

After market: 0.495 +0 (+0.61%)

0.492

-0.01 (-1.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners22.38%
Inst Owner Change0%
Ins Owners1.41%
Ins Owner Change-1.22%
Market Cap116.90M
Analysts80
Price Target4.18 (749.59%)
Short Float %11.12%
Short Ratio5.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.61%
Min EPS beat(2)-18.18%
Max EPS beat(2)-5.04%
EPS beat(4)1
Avg EPS beat(4)48.23%
Min EPS beat(4)-21.11%
Max EPS beat(4)237.26%
EPS beat(8)1
Avg EPS beat(8)-3.84%
EPS beat(12)5
Avg EPS beat(12)11.97%
EPS beat(16)8
Avg EPS beat(16)10.99%
Revenue beat(2)0
Avg Revenue beat(2)-30.27%
Min Revenue beat(2)-45.63%
Max Revenue beat(2)-14.91%
Revenue beat(4)1
Avg Revenue beat(4)3.42%
Min Revenue beat(4)-95.77%
Max Revenue beat(4)169.98%
Revenue beat(8)1
Avg Revenue beat(8)-27.6%
Revenue beat(12)3
Avg Revenue beat(12)28%
Revenue beat(16)7
Avg Revenue beat(16)22.14%
PT rev (1m)-18%
PT rev (3m)-18%
EPS NQ rev (1m)-13.84%
EPS NQ rev (3m)-0.66%
EPS NY rev (1m)21.94%
EPS NY rev (3m)12.65%
Revenue NQ rev (1m)5.95%
Revenue NQ rev (3m)-41.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.82
P/FCF N/A
P/OCF N/A
P/B 23.83
P/tB 23.83
EV/EBITDA N/A
EPS(TTM)-0.39
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0.27
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -149.17%
ROE -2620.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-95.5%
ROA(5y)-64.82%
ROE(3y)-268.79%
ROE(5y)-175.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.76
Quick Ratio 0.76
Altman-Z -28.39
F-Score5
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)104.2%
Cap/Depr(5y)163.67%
Cap/Sales(3y)10.21%
Cap/Sales(5y)12.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.15%
EPS Next Y28.04%
EPS Next 2Y14.12%
EPS Next 3Y15.86%
EPS Next 5Y12.2%
Revenue 1Y (TTM)243.09%
Revenue growth 3Y-19.48%
Revenue growth 5Y-10.81%
Sales Q2Q%1238.25%
Revenue Next Year-11.11%
Revenue Next 2Y-6.16%
Revenue Next 3Y19.6%
Revenue Next 5Y35.71%
EBIT growth 1Y43.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.78%
EBIT Next 3Y10.27%
EBIT Next 5Y28.89%
FCF growth 1Y82.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.67%
OCF growth 3YN/A
OCF growth 5YN/A